ArticleDermatology and therapy2026
Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia areata (AA) is a common autoimmune disease characterized by nonscarring hair loss, yet real-world data on AA in Mexico are sparse. This study aimed to characterize disease burden and identify unmet treatment needs among patients with AA in Mexico.
methodsClinical data were analyzed from Adelphi Real World's AA II Mexico Disease Specific Programme™ (October 2024-April 2025), a linked physician and patient cross-sectional survey with retrospective elements. Dermatologists provided clinical and treatment information for eight consecutive patients with AA within prespecified severity quotas (three mild, three moderate, and two severe/very severe). Patients completed the Hospital Anxiety and Depression Scale, the Alopecia Areata Patient Priority Outcomes instrument, and the Skindex-16 AA questionnaire. Analyses were stratified by physician-assessed AA severity (mild, moderate, severe/very severe).
resultsOf the 319 patients included, 123 had mild, 112 moderate, and 84 severe/very severe AA. Disease duration, percent scalp hair loss, nonscalp hair loss (eyebrow, eyelash, and body), and hair regrowth at consultation differed significantly across severity groups. Traditional medications, such as intralesional, topical, and oral corticosteroids, were the most frequently prescribed treatments across all severity groups. Physician-reported satisfaction with current treatment decreased with increasing AA severity and was significantly different across severity groups (P < 0.0001). Overall, 23.0% of patients with moderate AA and 29.0% with severe/very severe AA reported satisfaction with their current treatment and believed the best control had been achieved compared with 60.6% of patients with mild AA (P < 0.0001). Patients with severe/very severe AA experienced greater quality-of-life impairment and higher rates of anxiety and depression.
conclusionThis study helps address the gap in real-world evidence on AA in Mexico. The reliance on traditional therapies, combined with low treatment satisfaction among physicians and patients with moderate to very severe AA, suggests a need for improved access to advanced therapies within the Mexican healthcare system.
Indexed as
Identifiers
42842111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.